Immunotherapy treatments garnered a great deal of attention at the Annual Meeting of the American Society of Clinical Oncology (ASCO). This article from the New York Times discusses this form of treatment and its importance in cancer research.
At last year’s ASCO annual meeting, many doctors predicted a revolution in immunotherapy treatment.
“It’s a completely different world for patients with metastatic melanoma, to talk about the majority of patients being alive for years rather than weeks or months,” said Dr. Jedd D. Wolchok, a melanoma specialist at the Memorial Sloan-Kettering Cancer Center.
Fewer astonishing results have been presented at this year’s event, but there is some good news. New data shows the effects of the drugs can last for a long time, years in some cases. And there is now evidence that the drugs work on a growing number of types of cancer.
